Pfizer Data Says RSV Vaccine 82 Percent Effective in Newborns When Given to Pregnant Mothers

FDA says neurological disorder an 'important potential risk' associated with shot

A human respiratory syncytial virus, also known as RSV, shown in a 1981 electron microscope image. Centers for Disease Control and Prevention via AP

An experimental vaccine targeting respiratory syncytial virus (RSV) was found to be nearly 82 percent effective for infants when administered to pregnant mothers, said data published by Pfizer on Wednesday.

Final data from the study was published in the  New England Journal of Medicine. The paper also said that the shot is 86 percent effective in preventing RSV infections in older adults.